Vimta Labs Limited has announced the rescheduling of its previously scheduled analyst and institutional investor meeting with Valcore Capital, along with the addition of a new meeting with CVC Partners. Both meetings are now set to take place on March 31, 2026, as part of the company's ongoing investor engagement activities under regulatory compliance requirements.

Updated Meeting Schedule

The company has provided revised details for the rescheduled meeting with Valcore Capital and announced an additional meeting with CVC Partners on the same day. Both interactions will be conducted in online mode, providing direct communication channels between the company management and institutional investors.

Rescheduling Context

The original meeting with Valcore Capital was initially scheduled for March 27, 2026, at 3:00 PM (IST). The company has now moved this meeting to March 31, 2026, with an extended duration from 3:00 PM to 4:00 PM (IST). The rescheduling was made based on mutual availability of both the management and the participants.

Regulatory Compliance

Vimta Labs has maintained its commitment to transparency while adhering to regulatory guidelines. The company has specifically stated that no unpublished price sensitive information pertaining to the company will be shared during either of the meetings with analysts and institutional investors.

The disclosure has been made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III. The company noted that the disclosure follows shorter notice provisions as permitted by SEBI circular dated February 25, 2025, with reference number SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/25 on Industry Standards.

Meeting Arrangements

The formal intimation regarding the rescheduling and additional meeting was signed by Sujani Vasireddi, Company Secretary and Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited as part of the mandatory disclosure requirements. The meetings have been arranged to ensure optimal engagement while maintaining operational efficiency for all parties involved in the discussions.

Vimta Labs Limited has successfully allotted 34,166 employee stock options under its Employee Stock Option Plan 2021, marking another milestone in its employee incentive program. The ESOP Allotment Committee of the Board of Directors approved this allotment during their meeting held on 09th March 2026.

Share Capital Enhancement

The allotment has resulted in a significant increase in the company's share capital structure. The exercise price for these options was set at ₹2/- per share, matching the face value of the equity shares.

ESOP Plan Details

The shares were allotted under the "Vimta Labs Employee Stock Option Plan 2021" to eligible employees of the company. The distinctive numbers for the newly allotted shares range from 48335190 to 48369355, both inclusive.

Regulatory Compliance and Listing

Vimta Labs Limited has fulfilled its regulatory obligations by informing both BSE Limited and National Stock Exchange of India Limited about this allotment. The company confirmed that the newly allotted shares will rank pari-passu with existing equity shares, ensuring equal rights and privileges for all shareholders.

The company is currently in the process of completing other formalities required for listing these allotted shares on both stock exchanges. The allotment was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Previous Approvals and Filings

The company had previously received in-principle listing approvals from both exchanges. BSE Limited provided approval for 6,63,234 equity shares in September 2021, with additional approval for 5,18,260 equity shares in August 2025 following a bonus issue application. Similarly, NSE granted approval for the initial tranche in August 2021 and the additional shares in September 2025.

The allotment reinforces Vimta Labs' commitment to employee participation in the company's growth through structured stock option programs, while maintaining compliance with all regulatory requirements.